Daewon Pharmaceutical Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Seung-Ryel Baek
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 16.3yrs |
| CEO ownership | 16.0% |
| Management average tenure | no data |
| Board average tenure | 16.3yrs |
Recent management updates
Recent updates
There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings
Mar 21
Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Mar 26Is Daewon Pharmaceutical Co., Ltd. (KRX:003220) A Smart Pick For Income Investors?
Mar 07Do Insiders Own Lots Of Shares In Daewon Pharmaceutical Co., Ltd. (KRX:003220)?
Feb 18Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Jan 31
Did You Miss Daewon Pharmaceutical's (KRX:003220) 26% Share Price Gain?
Jan 13Here's What We Like About Daewon Pharmaceutical's (KRX:003220) Upcoming Dividend
Dec 24Daewon Pharmaceutical (KRX:003220) Seems To Use Debt Quite Sensibly
Dec 10Does Daewon Pharmaceutical Co., Ltd. (KRX:003220) Have A Place In Your Dividend Portfolio?
Nov 22CEO
Seung-Ryel Baek (65 yo)
16.3yrs
Tenure
Mr. Seung-Ryel Baek serves as the Chief Executive Officer of Daewon Pharmaceutical Co. Ltd., and has also been its Director since March 14, 2008. Mr. Baek serves as President of Daewon Pharmaceutical Co. L...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman | 16.3yrs | no data | 16.05% ₩ 48.6b | |
| Chairman | 16.3yrs | no data | 15.83% ₩ 47.9b | |
| Director | 15.3yrs | no data | no data |
16.3yrs
Average Tenure
Experienced Board: A003220's board of directors are seasoned and experienced ( 16.3 years average tenure).